A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Non-fasting Conditions
Status:
Completed
Trial end date:
2002-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the relative bioavailability of 500 mg Metformin
Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co. with that of 500 mg
CLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 500
mg extended-release tablet) in healthy adult volunteers under non-fasting conditions.